Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Emergent BioSolutions Inc.EBS · Entity 5902 | Director · President and CEO | June 09, 2023 | June 14, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Emergent BioSolutions Inc.
Report date June 09, 2023 · Filed June 14, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 506,059 |
Ending reported balance
After 2023-06-09 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-06-09 · Grant · Acquired 70,769 · Balance 364,520 F1: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company or the day prior to the annual shareholder meeting; whichever is earlier. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Row 2 · 2023-06-09 · Grant · Acquired 141,539 · Balance 506,059 F2: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%. |
| Employee Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.39 · Expires 2030-06-08 | Direct | 535,051 |
Reported balance
After 2023-06-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-09 · Grant · Acquired 141,539 · Balance 535,051 F3: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. F4: Represents the corrected number of securities owned due to a computational error in prior Form-4s |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company or the day prior to the annual shareholder meeting; whichever is earlier. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.
F2: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%.
F3: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.
F4: Represents the corrected number of securities owned due to a computational error in prior Form-4s
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2020 Filed Feb 28, 2020 02:17 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 16,683 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-20-000015 · wf-form4_158285623669698.xml · nonDerivative · entry 2 Kramer Robert · CIK 0001380956 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,760 F2 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue for the 2020 - 2022 fiscal years, as certified by the Compensation Committee following the performance period. Read SEC document |
| February 25, 2020 Filed Feb 28, 2020 02:17 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 16,683 | $0.00 | $0.00 |
DisclosureSEC source: 0001367644-20-000015 · wf-form4_158285623669698.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,077 F1 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| May 08, 2019 Filed May 10, 2019 21:16 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 95 | $47.49 | $4,511.55 |
DisclosureSEC source: 0001567619-19-010448 · doc1.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,394 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 00:35 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 1,941 | $58.71 | $113,956.11 |
DisclosureSEC source: 0001567619-19-005678 · doc1.xml · nonDerivative · entry 5 Kramer Robert · CIK 0001380956 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,489 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 00:35 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 779 | $57.98 | $45,166.42 |
DisclosureSEC source: 0001567619-19-005678 · doc1.xml · nonDerivative · entry 4 Kramer Robert · CIK 0001380956 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,430 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 26, 2019 Filed Mar 1, 2019 00:35 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Option (Right to Buy) · Derivative | 47,197 | $61.01 Strike: $61.01 | $2,879,488.97 |
DisclosureSEC source: 0001567619-19-005678 · doc1.xml · derivative · entry 6 Kramer Robert · CIK 0001380956 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,197 Underlying: Common Stock · 47,197 shares Expires 2026-02-25 F4 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant. Read SEC document |
| February 26, 2019 Filed Mar 1, 2019 00:35 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 11,801 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-005678 · doc1.xml · nonDerivative · entry 3 Kramer Robert · CIK 0001380956 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,209 F3 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2021 fiscal year, as certified by the Compensation Committee following the performance period. Read SEC document |
| February 26, 2019 Filed Mar 1, 2019 00:35 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 11,801 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-005678 · doc1.xml · nonDerivative · entry 2 Kramer Robert · CIK 0001380956 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,408 F2 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| February 26, 2019 Filed Mar 1, 2019 00:35 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 565 | $61.01 | $34,470.65 |
DisclosureSEC source: 0001567619-19-005678 · doc1.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,607 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| May 08, 2018 Filed May 10, 2018 20:37 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Option · Derivative | 2,586 | $48.33 Strike: $48.33 | $124,981.38 |
DisclosureSEC source: 0001140361-18-022810 · doc1.xml · derivative · entry 4 Kramer Robert · CIK 0001380956 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,586 Underlying: Common Stock · 2,586 shares Expires 2025-05-07 F5 · derivative.exercise_date: Vests on May 7, 2019; May 7, 2020 and May 7, 2021 in equal annual installments. Read SEC document |
| May 08, 2018 Filed May 10, 2018 20:37 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 646 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-022810 · doc1.xml · nonDerivative · entry 2 Kramer Robert · CIK 0001380956 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,172 F3 · shares: Consists of performance stock units granted under the Amended and Restated 2006 Emergent BioSolutions Inc. Stock Incentive Plan, as amended. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to net income as a percentage of total revenue for the 2020 fiscal year, each as determined in accordance with GAAP, as certified by the Compensation Committee following the performance period. Read SEC document |
| May 08, 2018 Filed May 10, 2018 20:37 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 647 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-022810 · doc1.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · President and COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,526 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 22:18 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 1,727 | $51.84 | $89,527.68 |
DisclosureSEC source: 0001140361-18-013320 · doc1.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · EVP, Administration and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,879 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 22:04 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 1,545 | $49.97 | $77,203.65 |
DisclosureSEC source: 0001140361-18-011288 · doc1.xml · nonDerivative · entry 4 Kramer Robert · CIK 0001380956 · EVP, Administration and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,606 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 22:04 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Option (right to buy) · Derivative | 23,670 | $49.64 Strike: $49.64 | $1,174,978.80 |
DisclosureSEC source: 0001140361-18-011288 · doc1.xml · derivative · entry 6 Kramer Robert · CIK 0001380956 · EVP, Administration and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,670 Underlying: Common Stock · 23,670 shares Expires 2025-02-26 F4 · derivative.exercise_date: Vests in three equal installments on February 26, 2019, February 26, 2020 and February 26, 2021. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 22:04 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 778 | $49.64 | $38,619.92 |
DisclosureSEC source: 0001140361-18-011288 · doc1.xml · nonDerivative · entry 3 Kramer Robert · CIK 0001380956 · EVP, Administration and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,151 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 22:04 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,917 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-011288 · doc1.xml · nonDerivative · entry 2 Kramer Robert · CIK 0001380956 · EVP, Administration and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,929 F3 · shares: Consists of performance stock units granted under the Amended and Restated 2006 Emergent BioSolutions Inc. Stock Incentive Plan, as amended. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to net income as a percentage of total revenue for the 2020 fiscal year, each as determined in accordance with GAAP, as certified by the Compensation Committee following the performance period. Read SEC document |
| February 27, 2018 Filed Mar 1, 2018 22:04 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 5,917 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-011288 · doc1.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · EVP, Administration and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,012 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F2 · shares: These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement. Read SEC document |
| March 10, 2017 Filed Mar 11, 2017 02:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 3,007 | $31.05 | $93,367.35 |
DisclosureSEC source: 0001140361-17-011682 · doc1.xml · nonDerivative · entry 2 Kramer Robert · CIK 0001380956 · EVP, Corproate Services Div 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,095 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| March 09, 2017 Filed Mar 11, 2017 02:30 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 1,908 | $30.98 | $59,109.84 |
DisclosureSEC source: 0001140361-17-011682 · doc1.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · EVP, Corproate Services Div 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,102 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 02:58 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantEmployee Stock Option (Right to buy) · Derivative | 32,638 | $0.00 Strike: $30.63 | $0.00 |
DisclosureSEC source: 0001140361-17-010396 · doc1.xml · derivative · entry 10 Kramer Robert · CIK 0001380956 · EVP, Corproate Services Div 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,638 Underlying: Common Stock · 32,638 shares Expires 2024-02-27 F8 · derivative.exercise_date: Consists of an option granted on 03/10/2015 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 02:58 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 1,799 | $30.63 | $55,103.37 |
DisclosureSEC source: 0001140361-17-010396 · doc1.xml · nonDerivative · entry 6 Kramer Robert · CIK 0001380956 · EVP, Corproate Services Div 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,010 Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 02:58 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 8,162 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-010396 · doc1.xml · nonDerivative · entry 5 Kramer Robert · CIK 0001380956 · EVP, Corproate Services Div 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,809 F5 · shares: Consists of performance stock units granted under the Amended and Restated 2006 Emergent BioSolutions Inc. Stock Incentive Plan, as amended. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to net income as a percentage of total revenue for the 2019 fiscal year, each as determined in accordance with GAAP, as certified by the Compensation Committee following the performance period. Read SEC document |
| February 28, 2017 Filed Mar 3, 2017 02:58 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | GrantCommon Stock | 8,161 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-010396 · doc1.xml · nonDerivative · entry 4 Kramer Robert · CIK 0001380956 · EVP, Corproate Services Div 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,647 F4 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| August 01, 2016 Filed Mar 3, 2017 02:58 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherEmployee Stock Option (Right to buy) · Derivative | 2,847 | $0.00 Strike: $30.86 | $0.00 |
DisclosureSEC source: 0001140361-17-010396 · doc1.xml · derivative · entry 9 Kramer Robert · CIK 0001380956 · EVP, Corproate Services Div 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,397 Underlying: Common Stock · 2,847 shares Expires 2023-02-28 F9 · security: Consists of an option granted on 03/01/2016 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant. F6 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| August 01, 2016 Filed Mar 3, 2017 02:58 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherEmployee Stock Option (Right to buy) · Derivative | 2,121 | $0.00 Strike: $26.45 | $0.00 |
DisclosureSEC source: 0001140361-17-010396 · doc1.xml · derivative · entry 8 Kramer Robert · CIK 0001380956 · EVP, Corproate Services Div 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,132 Underlying: Common Stock · 2,847 shares Expires 2022-03-09 F8 · security: Consists of an option granted on 03/10/2015 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant. F6 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| August 01, 2016 Filed Mar 3, 2017 02:58 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherEmployee Stock Option (Right to buy) · Derivative | 1,672 | $25.62 Strike: $25.62 | $42,836.64 |
DisclosureSEC source: 0001140361-17-010396 · doc1.xml · derivative · entry 7 Kramer Robert · CIK 0001380956 · EVP, Corproate Services Div 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,026 Underlying: Common Stock · 1,672 shares Expires 2021-03-10 F7 · derivative.exercise_date: Consists of an option granted on 03/11/2014 under the company's stock incentive plan as amended and restated. In connection with the spin-off on August 1, 2016, the reporting person received a grant of additional stock options as a result of an adjustment to preserve the pre-spin intrinsic value of an existing stock option grant. The adjustments included an adjustment to the stock option price of the grant. Read SEC document |
| August 01, 2016 Filed Mar 3, 2017 02:58 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherCommon Stock | 1,425 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-010396 · doc1.xml · nonDerivative · entry 3 Kramer Robert · CIK 0001380956 · EVP, Corproate Services Div 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,486 F3 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017, March 2018 and March 2019. Read SEC document |
| August 01, 2016 Filed Mar 3, 2017 02:58 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherCommon Stock | 1,061 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-010396 · doc1.xml · nonDerivative · entry 2 Kramer Robert · CIK 0001380956 · EVP, Corproate Services Div 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,061 F2 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017 and March 2018. Read SEC document |
| August 01, 2016 Filed Mar 3, 2017 02:58 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | OtherCommon Stock | 1,672 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-010396 · doc1.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · EVP, Corproate Services Div 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 F1 · security: In connection with the spin-off of Aptevo Therapeutics Inc. from Emergent BioSolutions Inc, on August 1, 2016 the reporting person received a grant of restricted stock units as a result of an adjustment to an existing Emergent restricted stock unit grant held by the reporting person prior to the spin-off. The restricted stock units vest in March 2017. Read SEC document |
| April 01, 2016 Filed Feb 24, 2017 15:05 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option · Derivative | 5,503 | $0.00 Strike: $29.00 | $0.00 |
DisclosureSEC source: 0001140361-17-008973 · doc1.xml · derivative · entry 15 Kramer Robert · CIK 0001380956 · EVP, Corporate Services Divisi 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,514 Underlying: Common Stock · 5,503 shares Expires 2022-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Consists of an option granted under the company's stock incentive plan on March 10, 2015. F17 · derivative.exercise_date: The option vest in three equal installments in March 2016, 2017 and 2018. Read SEC document |
| April 01, 2016 Filed Feb 24, 2017 15:05 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option · Derivative | 17,354 | $0.00 Strike: $28.09 | $0.00 |
DisclosureSEC source: 0001140361-17-008973 · doc1.xml · derivative · entry 14 Kramer Robert · CIK 0001380956 · EVP, Corporate Services Divisi 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,708 Underlying: Common Stock · 17,354 shares Expires 2021-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Consists of an option granted under the company's stock incentive plan on March 11, 2014. F16 · derivative.exercise_date: The option vest in three equal installments in March 2015, 2016 and 2017. Read SEC document |
| April 01, 2016 Filed Feb 24, 2017 15:05 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option · Derivative | 3,939 | $0.00 Strike: $14.67 | $0.00 |
DisclosureSEC source: 0001140361-17-008973 · doc1.xml · derivative · entry 13 Kramer Robert · CIK 0001380956 · EVP, Corporate Services Divisi 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,940 Underlying: Common Stock · 3,939 shares Expires 2020-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Consists of an option granted under the company's stock incentive plan on March 12, 2013. F15 · derivative.exercise_date: The option vest in three equal installments in March 2014, 2015 and 2016. Read SEC document |
| April 01, 2016 Filed Feb 24, 2017 15:05 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option · Derivative | 11,531 | $0.00 Strike: $14.41 | $0.00 |
DisclosureSEC source: 0001140361-17-008973 · doc1.xml · derivative · entry 12 Kramer Robert · CIK 0001380956 · EVP, Corporate Services Divisi 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,531 Underlying: Common Stock · 11,531 shares Expires 2019-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Consists of an option granted under the company's stock incentive plan on November 5, 2012. F14 · derivative.exercise_date: The option vested in three equal installments in November 2013, 2014 and 2015. Read SEC document |
| April 01, 2016 Filed Feb 24, 2017 15:05 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 2,945 | $35.73 | $105,224.85 |
DisclosureSEC source: 0001140361-17-008973 · doc1.xml · nonDerivative · entry 11 Kramer Robert · CIK 0001380956 · EVP, Corporate Services Divisi 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,831 F10 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F1 · kind: These sales were executed pursuant to a 10b5-1 trading plan adopted by the reporting person on February 29, 2016. F13 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.50 to $36.32, inclusive. Read SEC document |
| April 01, 2016 Filed Feb 24, 2017 15:05 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 1,855 | $35.80 | $66,409.00 |
DisclosureSEC source: 0001140361-17-008973 · doc1.xml · nonDerivative · entry 10 Kramer Robert · CIK 0001380956 · EVP, Corporate Services Divisi 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,776 F10 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F1 · kind: These sales were executed pursuant to a 10b5-1 trading plan adopted by the reporting person on February 29, 2016. F12 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.50 to $36.13, inclusive. Read SEC document |
| April 01, 2016 Filed Feb 24, 2017 15:05 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 445 | $35.93 | $15,988.85 |
DisclosureSEC source: 0001140361-17-008973 · doc1.xml · nonDerivative · entry 9 Kramer Robert · CIK 0001380956 · EVP, Corporate Services Divisi 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,631 F10 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. F1 · kind: These sales were executed pursuant to a 10b5-1 trading plan adopted by the reporting person on February 29, 2016. F11 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.91 to $36.00, inclusive. Read SEC document |
| April 01, 2016 Filed Feb 24, 2017 15:05 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 5,503 | $35.66 | $196,236.98 |
DisclosureSEC source: 0001140361-17-008973 · doc1.xml · nonDerivative · entry 8 Kramer Robert · CIK 0001380956 · EVP, Corporate Services Divisi 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,076 F5 · security: Consists of an option granted under the company's stock incentive plan on March 10, 2015. F1 · kind: These sales were executed pursuant to a 10b5-1 trading plan adopted by the reporting person on February 29, 2016. F9 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.12 to $36.42, inclusive. Read SEC document |
| April 01, 2016 Filed Feb 24, 2017 15:05 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 5,503 | $29.00 | $159,587.00 |
DisclosureSEC source: 0001140361-17-008973 · doc1.xml · nonDerivative · entry 7 Kramer Robert · CIK 0001380956 · EVP, Corporate Services Divisi 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,579 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Consists of an option granted under the company's stock incentive plan on March 10, 2015. Read SEC document |
| April 01, 2016 Filed Feb 24, 2017 15:05 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 17,354 | $35.48 | $615,719.92 |
DisclosureSEC source: 0001140361-17-008973 · doc1.xml · nonDerivative · entry 6 Kramer Robert · CIK 0001380956 · EVP, Corporate Services Divisi 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,076 F4 · security: Consists of an option granted under the company's stock incentive plan on March 11, 2014. F1 · kind: These sales were executed pursuant to a 10b5-1 trading plan adopted by the reporting person on February 29, 2016. F8 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.07 to $36.35, inclusive. Read SEC document |
| April 01, 2016 Filed Feb 24, 2017 15:05 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 17,354 | $28.09 | $487,473.86 |
DisclosureSEC source: 0001140361-17-008973 · doc1.xml · nonDerivative · entry 5 Kramer Robert · CIK 0001380956 · EVP, Corporate Services Divisi 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Consists of an option granted under the company's stock incentive plan on March 11, 2014. Read SEC document |
| April 01, 2016 Filed Feb 24, 2017 15:05 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 3,939 | $35.74 | $140,779.86 |
DisclosureSEC source: 0001140361-17-008973 · doc1.xml · nonDerivative · entry 4 Kramer Robert · CIK 0001380956 · EVP, Corporate Services Divisi 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,076 F3 · security: Consists of an option granted under the company's stock incentive plan on March 12, 2013. F1 · kind: These sales were executed pursuant to a 10b5-1 trading plan adopted by the reporting person on February 29, 2016. F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.37 to $36.32, inclusive. Read SEC document |
| April 01, 2016 Filed Feb 24, 2017 15:05 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 3,939 | $14.67 | $57,785.13 |
DisclosureSEC source: 0001140361-17-008973 · doc1.xml · nonDerivative · entry 3 Kramer Robert · CIK 0001380956 · EVP, Corporate Services Divisi 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,015 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Consists of an option granted under the company's stock incentive plan on March 12, 2013. Read SEC document |
| April 01, 2016 Filed Feb 24, 2017 15:05 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 11,531 | $35.49 | $409,235.19 |
DisclosureSEC source: 0001140361-17-008973 · doc1.xml · nonDerivative · entry 2 Kramer Robert · CIK 0001380956 · EVP, Corporate Services Divisi 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,076 F2 · security: Consists of an option granted under the company's stock incentive plan on November 5, 2012. F1 · kind: These sales were executed pursuant to a 10b5-1 trading plan adopted by the reporting person on February 29, 2016. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.11 to $36.34, inclusive. Read SEC document |
| April 01, 2016 Filed Feb 24, 2017 15:05 UTC Amendment | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 11,531 | $14.41 | $166,161.71 |
DisclosureSEC source: 0001140361-17-008973 · doc1.xml · nonDerivative · entry 1 Kramer Robert · CIK 0001380956 · EVP, Corporate Services Divisi 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,607 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Consists of an option granted under the company's stock incentive plan on November 5, 2012. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.